These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

339 related items for PubMed ID: 25166271

  • 1. Comparison of visual prognoses between natural course of simple hemorrhage and choroidal neovascularization treated with intravitreal bevacizumab in highly myopic eyes: a 1-year follow-up.
    Goto S, Sayanagi K, Ikuno Y, Jo Y, Gomi F, Nishida K.
    Retina; 2015 Mar; 35(3):429-34. PubMed ID: 25166271
    [Abstract] [Full Text] [Related]

  • 2. Intravitreal bevacizumab for choroidal neovascularization attributable to pathological myopia: one-year results.
    Ikuno Y, Sayanagi K, Soga K, Sawa M, Tsujikawa M, Gomi F, Tano Y.
    Am J Ophthalmol; 2009 Jan; 147(1):94-100.e1. PubMed ID: 18774550
    [Abstract] [Full Text] [Related]

  • 3. Central retinal sensitivity after intravitreal injection of bevacizumab for myopic choroidal neovascularization.
    Yodoi Y, Tsujikawa A, Nakanishi H, Otani A, Tamura H, Ojima Y, Hayashi H, Yoshimura N.
    Am J Ophthalmol; 2009 May; 147(5):816-24, 824.e1. PubMed ID: 19211092
    [Abstract] [Full Text] [Related]

  • 4. Prognostic factors of eyes with naïve subfoveal myopic choroidal neovascularization after intravitreal bevacizumab.
    Yang HS, Kim JG, Kim JT, Joe SG.
    Am J Ophthalmol; 2013 Dec; 156(6):1201-1210.e2. PubMed ID: 24075429
    [Abstract] [Full Text] [Related]

  • 5. Prognostic factors for visual outcome after intravitreal anti-VEGF injection for naive myopic choroidal neovascularization.
    Yoon JU, Kim YM, Lee SJ, Byun YJ, Koh HJ.
    Retina; 2012 May; 32(5):949-55. PubMed ID: 22534553
    [Abstract] [Full Text] [Related]

  • 6. Comparison between anti-vascular endothelial growth factor therapy and photodynamic therapy for myopic choroidal neovascularization.
    Matsuo M, Honda S, Matsumiya W, Kusuhara S, Tsukahara Y, Negi A.
    Eur J Ophthalmol; 2012 May; 22(2):210-5. PubMed ID: 21534251
    [Abstract] [Full Text] [Related]

  • 7. Intravitreal bevacizumab vs sub-tenon triamcinolone acetonide for choroidal neovascularization attributable to pathologic myopia.
    Wakabayashi T, Ikuno Y, Gomi F, Hamasaki T, Tano Y.
    Am J Ophthalmol; 2009 Oct; 148(4):591-596.e1. PubMed ID: 19589497
    [Abstract] [Full Text] [Related]

  • 8. Multifocal electroretinography and optical coherence tomography changes after repeated intravitreal bevacizumab (Avastin) in myopic choroidal neovascularization.
    Sabry D, Gad MA, Enam KM.
    Retina; 2013 Mar; 33(3):598-605. PubMed ID: 23064427
    [Abstract] [Full Text] [Related]

  • 9. Combined photodynamic therapy with intravitreal bevacizumab injections for polypoidal choroidal vasculopathy: long-term visual outcome.
    Kang HM, Koh HJ, Lee CS, Lee SC.
    Am J Ophthalmol; 2014 Mar; 157(3):598-606.e1. PubMed ID: 24269378
    [Abstract] [Full Text] [Related]

  • 10. Intravitreal bevacizumab therapy on an as-per-needed basis in subfoveal choroidal neovascularization secondary to pathological myopia: 2-year outcomes of a prospective case series.
    Iacono P, Parodi MB, Papayannis A, Kontadakis S, Sheth S, Bandello F.
    Retina; 2011 Oct; 31(9):1841-7. PubMed ID: 21775926
    [Abstract] [Full Text] [Related]

  • 11. Twelve-month outcome after one intravitreal injection of bevacizumab to treat myopic choroidal neovascularization.
    Ruiz-Moreno JM, Montero JA, Arias L, Araiz J, Gomez-Ulla F, Silva R, Piñero DP.
    Retina; 2010 Oct; 30(10):1609-15. PubMed ID: 20856171
    [Abstract] [Full Text] [Related]

  • 12. Ranibizumab for choroidal neovascularization associated with adult-onset foveomacular vitelliform dystrophy: one-year results.
    Mimoun G, Caillaux V, Querques G, Rothschild PR, Puche N, Souied EH.
    Retina; 2013 Mar; 33(3):513-21. PubMed ID: 23400081
    [Abstract] [Full Text] [Related]

  • 13. Long-term effectiveness of intravitreal bevacizumab for choroidal neovascularization secondary to angioid streaks in pseudoxanthoma elasticum.
    Finger RP, Charbel Issa P, Schmitz-Valckenberg S, Holz FG, Scholl HN.
    Retina; 2011 Mar; 31(7):1268-78. PubMed ID: 21386758
    [Abstract] [Full Text] [Related]

  • 14. Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularization: six-month results of a prospective pilot study.
    Chan WM, Lai TY, Liu DT, Lam DS.
    Ophthalmology; 2007 Dec; 114(12):2190-6. PubMed ID: 17599414
    [Abstract] [Full Text] [Related]

  • 15. Different dosing of intravitreal bevacizumab for choroidal neovascularization because of pathologic myopia.
    Wakabayashi T, Ikuno Y, Gomi F.
    Retina; 2011 May; 31(5):880-6. PubMed ID: 21242860
    [Abstract] [Full Text] [Related]

  • 16. Intravitreal ranibizumab for choroidal neovascularization complicating pathologic myopia.
    Lalloum F, Souied EH, Bastuji-Garin S, Puche N, Querques G, Glacet-Bernard A, Coscas G, Soubrane G, Leveziel N.
    Retina; 2010 Mar; 30(3):399-406. PubMed ID: 20038864
    [Abstract] [Full Text] [Related]

  • 17. One-year outcome of two different initial dosing regimens of intravitreal ranibizumab for myopic choroidal neovascularization.
    Kung YH, Wu TT, Huang YH.
    Acta Ophthalmol; 2014 Dec; 92(8):e615-20. PubMed ID: 24924911
    [Abstract] [Full Text] [Related]

  • 18. Three-year visual outcome of photodynamic therapy plus intravitreal bevacizumab with or without subtenon triamcinolone acetonide injections for polypoidal choroidal vasculopathy.
    Sakai T, Ohkuma Y, Kohno H, Hayashi T, Watanabe A, Tsuneoka H.
    Br J Ophthalmol; 2014 Dec; 98(12):1642-8. PubMed ID: 25053762
    [Abstract] [Full Text] [Related]

  • 19. Intravitreal bevacizumab as a treatment for choroidal neovascularisation secondary to myopia: 4-year study results.
    Peiretti E, Vinci M, Fossarello M.
    Can J Ophthalmol; 2012 Feb; 47(1):28-33. PubMed ID: 22333848
    [Abstract] [Full Text] [Related]

  • 20. Intravitreal bevacizumab for exudative branching vascular networks in polypoidal choroidal vasculopathy.
    Wakabayashi T, Gomi F, Sawa M, Tsujikawa M, Nishida K.
    Br J Ophthalmol; 2012 Mar; 96(3):394-9. PubMed ID: 21719568
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.